Futura Medical has announced stellar data from the first clinical trial of MED2002 (Eroxon™). The data shows not only strong efficacy vs. placebo (p=0.0001), but also an excellent safety & tolerability profile and a faster onset of action than currently approved ED products. We believe the market potential is significant, and will update our forecasts as soon as the commercialisation strategy for the product has been clarified. In our view, the product addresses a significant unmet need: it has ....
07 Sep 2016
N+1 Singer - Futura Medical - Stellar data from pivotal MED2002 (Eroxon™) trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Futura Medical - Stellar data from pivotal MED2002 (Eroxon™) trial
Futura Medical plc (FUM:LON) | 39.4 0.2 1.5% | Mkt Cap: 118.8m
- Published:
07 Sep 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
Futura Medical has announced stellar data from the first clinical trial of MED2002 (Eroxon™). The data shows not only strong efficacy vs. placebo (p=0.0001), but also an excellent safety & tolerability profile and a faster onset of action than currently approved ED products. We believe the market potential is significant, and will update our forecasts as soon as the commercialisation strategy for the product has been clarified. In our view, the product addresses a significant unmet need: it has ....